{"id":"moxifloxacin-dexamethasone-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Increased intraocular pressure (with prolonged corticosteroid use)"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Photophobia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin works by inhibiting bacterial DNA replication and repair enzymes, making it effective against a broad spectrum of ocular pathogens. Dexamethasone suppresses the inflammatory response by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene production. Together, this combination addresses both the infectious and inflammatory components of ocular conditions.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that reduces inflammation in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:10.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Post-operative ocular inflammation and infection"},{"name":"Corneal ulcers with bacterial infection"}]},"trialDetails":[{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT03580473","phase":"PHASE2","title":"Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification","status":"COMPLETED","sponsor":"EMS","startDate":"2020-02-27","conditions":"Ocular Inflammation, Cataract","enrollment":118},{"nctId":"NCT01515826","phase":"PHASE3","title":"VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2014-03","conditions":"Cataracts","enrollment":""},{"nctId":"NCT01859702","phase":"PHASE4","title":"Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-04","conditions":"Cataract","enrollment":36},{"nctId":"NCT00579020","phase":"PHASE2","title":"A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2007-12","conditions":"Corneal Infiltrates","enrollment":144},{"nctId":"NCT00732446","phase":"PHASE3","title":"Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2008-08","conditions":"Blepharitis, Conjunctivitis, Keratitis","enrollment":100},{"nctId":"NCT00870103","phase":"PHASE4","title":"Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Cataract","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRO-232"],"phase":"phase_3","status":"active","brandName":"Moxifloxacin / Dexamethasone Ophthalmic Solution","genericName":"Moxifloxacin / Dexamethasone Ophthalmic Solution","companyName":"Laboratorios Sophia S.A de C.V.","companyId":"laboratorios-sophia-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that reduces inflammation in the eye. Used for Bacterial conjunctivitis, Post-operative ocular inflammation and infection, Corneal ulcers with bacterial infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}